The Microtubule Destabilizer Eribulin Synergizes with STING Agonists to Promote Antitumor Efficacy in Triple-Negative Breast Cancer Models

The Microtubule Destabilizer Eribulin Synergizes with STING Agonists to Promote Antitumor Efficacy in Triple-Negative Breast Cancer Models

Eribulin is a microtubule destabilizer used in the treatment of triple-negative breast cancer (TNBC). Eribulin and other microtubule targeted drugs, such as the taxanes, have shared antimitotic effects, but differ in their mechanism of microtubule disruption, leading to diverse effects on cellular s...

Full description

Bibliographic Details
Main Authors: Leila Takahashi-Ruiz, Charles S. Fermaintt, Nancy J. Wilkinson, Peter Y. W. Chan, Susan L. Mooberry, April L. Risinger
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Cancers
Subjects:
triple-negative breast cancer
eribulin
cGAS-STING
microtubule-targeting agents
microtubule destabilizers
type I interferons
Online Access:https://www.mdpi.com/2072-6694/14/23/5962

Internet

https://www.mdpi.com/2072-6694/14/23/5962

Similar Items